Copy of Newspaper publication for audited results for year ended 31st March,2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Drugs Limited has published its audited financial results for the fourth quarter and full year ended 31 March 2026 in Financial Express (English) and Prajashakti (Telugu) on 30 May 2026, as required under SEBI Listing Regulations. Standalone revenue for FY26 jumped to Rs. 7,877.13 lakhs from Rs. 4,525.91 lakhs in FY25, a growth of about 74%. Net profit for FY26 more than tripled to Rs. 105.50 lakhs versus Rs. 33.62 lakhs in the previous year. Q4 FY26 alone delivered Rs. 3,789.89 lakhs in revenue with a profit of Rs. 52.80 lakhs, sharply higher than Rs. 1,039.65 lakhs revenue and Rs. 3.90 lakhs profit in Q4 FY25. Consolidated FY26 revenue stood at Rs. 7,588.30 lakhs with a profit of Rs. 103.74 lakhs, also showing strong year-on-year growth.
This is a regulatory newspaper publication of already-audited results, so the immediate stock impact is limited, but the numbers reflect a strong turnaround with revenue and profits rising sharply, which is a positive signal for shareholders and could improve investor sentiment.